Dr. Michael Quezada, MD

Dr. Quezada practices at Coastal Surgical Institute - HOPD in Pismo Beach, California.

Dr. Quezada's NPI, 1326466467, was assigned on April 5, 2014. Dr. Quezada graduated from Texas A&M College of Medicine - Bryan in 2014. Dr. Quezada's California license number on file is A140790.

Dr. Quezada's primary practice is Coastal Surgical Institute - HOPD, at 921 Oak Park Blvd, Pismo Beach, CA 93449.

Dr. Quezada's primary practice is Coastal Surgical Institute - HOPD in Pismo Beach, California. Dr. Quezada is also affiliated with Dignity Health - Marian Regional Medical Center. The medical group on file is Pacific Central Coast Health Centers Medical Group. Dmand AI also links Dr. Quezada to 3 more hospitals, 1 group practice or clinic and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Quezada practices, 7 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Quezada's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Quezada is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Quezada has a license on file in California.

Dmand AI lists acid reflux, acute gastroduodenitis, chronic indigestion, chronic inflammatory bowel disease (IBD), cirrhosis of the liver, colonoscopy, esophagus, stomach, or upper small intestine surgery and gastroenteritis among the conditions Dr. Quezada treats.

CMS data shows 1,013 Medicare services from Dr. Quezada across 13 procedure codes in 2024, for 589 Medicare patients. Medicare paid $118,514 for them.

CMS counts 589 Medicare patients who saw Dr. Quezada in 2024. The largest group is 65 to 74, with 329 patients. 74% of them have high cholesterol, and 66% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.11, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Quezada's median patient age at 63, with 53% women.

In 2024, Dr. Quezada wrote 505 Medicare Part D claims for 166 patients. 77% of them were for generic drugs. CMS names the drug for 367 of them, across 10 drugs with 11 or more claims each, at $52,893 in total drug cost. In 2023, CMS named 367 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Quezada for performance year 2024, reported through an alternative payment model (APM). Dr. Quezada accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Quezada as offering telehealth. CMS counts 243 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Quezada, more than 93% of the clinicians it reports for that procedure.

Dmand AI links 3 papers to Dr. Quezada, published from 2017 to 2019. The most frequent topics are Brain Neoplasms and Glioma. Dr. Quezada's most frequent co-authors are Michelle Leigh Monje, MD, PhD, James Leonard Buxbaum, MD and Ben Lin Da, MD.

CMS Open Payments shows 20 general payments to Dr. Quezada from 4 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 77% of the total. Boston Scientific Corporation paid the most, $500.

Dr. Quezada graduated from Texas A&M College of Medicine - Bryan in 2014.

Dr. Quezada is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.